Page 185 - 2019秋季手冊內頁-ebook測試

衛生福利部雙和醫院(委託臺北醫學大學興建經營)
Treatment
mFOLFOX 6 Cetuximab 400/250 mg/kg
Week 1 Week 2
Avelumab 10 mg/kg mFOLFOX 6
Cetuximab 250 mg/kg
Week 3 Week 4
Avelumab 10 mg/kg mFOLFOX 6
Cetuximab 250 mg/kg
 until secondary resection, progression or toxicity
Week 5
Week 6
Median number of treatment cycles (range)
oxaliplatin 5FU cetuximab avelumab
8 (1-34) 13 (1-35) 12 (1-35) 16 (0-34)
Duration of cetuximab and avelumab treatment median 5.4 months (range 0.7-18.4)
衛生福利部雙和醫院(委託臺北醫學大學興建經營)
Results – safety (n=43)
Grade 3/4 event (>5%)
Anemia, blood disorders, HUS
Abdominal pain, Diarrhea, others
Vomiting, Nausea
Fever, Fatique
Administration, Infusion related, Allergic Infection of Catheter, Device, Urinary
tract, others
Elevated creatinine, liver enzymes
Cognitive disturbance, Meningism,
Syncope, Psychiatric disorders
Peripheral sensory polyneuropathy, Paresthesia Skin reaction
Hematoma, Thromboembolic events Hypertension
Incidence n (% per patient) 7 (18%)
9 (24%) 5 (13%) 4 (10%) 6 (16%)
12 (32%)
5 (13%) 6 (16%)
6 (16%) 8 (21%) 5 (13%) 3 (8%)
• 52SAEsin23outof38 patients (61%)
• 1.37 SAEs per patient
186